solanezumab

Argus analyst Katelyn Bayone believes shares of Eli Lilly and Co (NYSE: LLY) are fairly valued at around $81, which prompted her to downgrade the stock from Buy to Hold. According to Bayone, shares are trading near their 52-week high and also at a superior valuation versus its peers. In fact, the...

Alzheimer's has proven to be one of the most stubborn diseases known to modern medicine. An incurable, devastating illness that inspires frustration — even anger — against and from the scientific community itself, which has failed to develop new, effective therapies. Susanne...

Shares of AC Immune Ltd (NASDAQ: ACIU), a medical biotechnology company that focuses on the treatment of Alzheimer's disease (AD) and other neurodegenerative diseases, soared higher by more than 23 percent after the company's partner Genentech published an editorial. AC Immune and Genentech have...

BMO Capital Markets said Biogen Inc (NASDAQ: BIIB) shares should trade higher, despite a recent drug trial miss, on CTAD data (Clinical Trials on Alzheimer's Disease). The CTAD data show: “Solanezumab caused small yet consistent improvements on secondary endpoints, including CDR-SB (...

Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...

After Eli Lilly and Co (NYSE: LLY) earlier announce the failure of its Alzeheimer’s candidate solanezumab, the entire Alzheimer's sector could feel the aftershocks. While some of the players have since recovered from early morning drops, a few are still in the red in early Wednesday...

Biogen Inc (NASDAQ: BIIB) is sliding more than 8 percent in a sympathy move after Eli Lilly and Co (NYSE: LLY) announced its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. Elaborating on the...

Eli Lilly and Co (NYSE: LLY) plunged 15 percent in the pre-market hours Wednesday after the company’s drug solanezumab failed to meet primary endpoint for the treatment of mild dementia due to Alzheimer's disease in a late-stage study. “Patients treated with solanezumab did not...

Eli Lilly and Co (NYSE: LLY) seems to be entering “a long lasting period of accelerating revenue and EPS growth driven by a diversified late stage pipeline propelling many years of margin expansion,” Goldman Sachs’ Jami Rubin said in a report. He upgraded the rating on the...

JPMorgan has upgraded Eli Lilly and Co (NYSE: LLY) to Overweight from Neutral based on the potential for new product driven upside to estimates in 2017 and beyond. The brokerage's bullish thesis also reflects a favorable risk/reward for solanezumab data in Alzheimer patients late this year. Notably...

The meat of large-cap pharmaceutical earnings season starts this week. Johnson & Johnson (NYSE: JNJ)’s strong Q1 report last week has Credit Suisse analyst Vamil Divan hopeful that AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and Eli Lilly and Co (NYSE: LLY) will be able...

Eli Lilly & Co. (NYSE: LLY) planned to go back to the drawing board with its new experimental Alzheimer’s drug, according Bloomberg. The drug, solanezumab, which was not successful with advanced Alzheimer’s patients, will be tested in patients who show signs of early stages of the disease...

Editor's note: This is the first in a series of articles that will be appearing on Benzinga.com over the next few months. Based on Paul Ryan's sentiments and personal history, the following companies would make a nice, diverse portfolio for vice presidential nominee. Shares of the following...